McGill Exercise With and Without 3-dimensional Myofascial Release Technique in Non-specific Low B… (NCT07441031) | Clinical Trial Compass
CompletedNot Applicable
McGill Exercise With and Without 3-dimensional Myofascial Release Technique in Non-specific Low Back Pain
Pakistan38 participantsStarted 2025-02-15
Plain-language summary
Low back pain is a complex of musculoskeletal disorders or muscular imbalance and one of the most common problems of patients referred to physiotherapy clinics, but still diagnosis and especially the provision of special back pain therapy is a challenge. According to the studies, 84% of the population at least once in a lifetime. Non-specific Lower back pain NSLBP does not have any specific cause and almost 90% of patients experience undiagnosed pathologic LBP. It is multifactorial and has different causes depends on the type of injury. Common etiologies behind NSLBP are muscular weakness, postural instability, fascial restriction, lumbo-pelvic muscle imbalance, change in spinal curvature and abnormal tilting of pelvic.
Who can participate
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pain rate 3-7 on NPRS.
* Localized back pain between the 12th rib and the gluteal folds.
* Hyperlordotic curvature of lumber spine beyond range 37° to 42°.
* No radiating pain or paresthesia during SLR.
* No evidence of congenital anomalies.
* Diagnosed hyprlordotic lumbar.
* Positive special test (mini 2): Thomas test, wall test, The modified Schöber technique test (MST), The fingertip-to-floor test and Straight leg raise test.
Exclusion Criteria:
* Individual with diagnosed neurological and rheumatologically disorder.
* History of abdominal, lumber or sacral spine, recent spinal surgery.
* Person on painkillers during last 3 months.
* Having history of spinal fracture.
* Females in post-partum period or pregnancy.
* History of Severe osteoporosis, Tumor.
* Severe heart failure or respiratory failure, active drug addiction, active psychiatric pathology.
* Intervertebral disc pathology.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.